US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Corgi U.S. Healthcare 2x Daily ETF

33.10

+0.91392.84%

Volume:2K

Turnover:64.18K

Market Cap:662.00K

PE:- -

High:33.11

Open:33.11

Low:33.10

Close:32.19

52wk High:35.56

52wk Low:25.40

Shares:20.00K

Float Shares:20.00K

Volume Ratio:7.76

T/O Rate:9.70%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches

Lucid Diagnostics advances Medicare reimbursement and coding infrastructure

Ultragenyx price target raised to $35 from $32 at Barclays

Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide

Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111

Ultragenyx confirms FDA approval of Fayuvi

Nuvation Bio announces FDA approval of sNDA for Ibtrozi

Bayer receives FDA approval for Kerendia for CKD with type 1 diabetes

ASX biotech expands diagnostics portfolio after FDA approval

Morning Star AU

Barclays downgrades Scholar Rock on valuation after FDA approval

Biofrontera announces FDA approval of Ameluz supplemental new drug application

Scholar Rock Wins FDA Approval for SMA Therapy

Scholar Rock price target raised to $84 from $76 at BMO Capital

Telix Wins FDA Nod for First FET-PET Glioma Imaging Drug Pixclara

Scholar Rock announces FDA approval of isembyld

Pharming wins FDA nod to extend Joenja use to younger APDS children

Medicare Advantage Patients Who Get Diagnosed with Alzheimer's or Other Serious Diseases are Ditching Their Plans - and it Can Cost Them

Guardant announces FDA approval of Guardant360 CDx as companion diagnostic

Medicare Advantage Patients Who Get Diagnosed with Alzheimer's or Other Serious Diseases are Ditching Their Plans - and it Can Cost Them

Medicare Advantage Patients Who Get Diagnosed with Alzheimer's or Other Serious Diseases are Ditching Their Plans - and it Can Cost Them

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/XLVX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"XLVX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XLVX\",,,,,undefined,":{"symbol":"XLVX","market":"US","secType":"STK","nameCN":"Corgi U.S. Healthcare 2x Daily ETF","latestPrice":33.1,"timestamp":1791576000000,"preClose":32.1861,"halted":0,"volume":1940,"delay":0,"changeRate":0.02839424472054701,"floatShares":20000,"shares":20000,"eps":0,"marketStatus":"Market Closed","change":0.9139,"latestTime":"10-09 16:00:00 EDT","open":33.11,"high":33.11,"low":33.1,"amount":64182,"amplitude":0.000311,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"exchange":"CBOE","adjPreClose":32.1861,"nav":32.17,"aum":643400,"bidAskSpread":0,"volumeRatio":7.7599956544024336},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XLVX\",,,,,undefined,":{"symbol":"XLVX","floatShares":20000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":7.7599956544024336,"shares":20000,"dividePrice":0,"high":33.11,"amplitude":0.000311,"preClose":32.1861,"low":33.1,"week52Low":25.3968,"pbRate":"--","week52High":35.56,"institutionHeld":0,"latestPrice":33.1,"eps":0,"divideRate":0,"volume":1940,"delay":0,"ttmEps":0,"open":33.11,"prevYearClose":25.46,"prevWeekClose":31.5253,"prevMonthClose":32.5588,"prevQuarterClose":32.5588,"fiveDayClose":31.5253,"twentyDayClose":31.1534,"sixtyDayClose":30.3159},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XLVX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XLVX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XLVX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XLVX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669437128","title":"Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches","url":"https://stock-news.laohu8.com/highlight/detail?id=2669437128","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669437128?lang=en_us&edition=fundamental","pubTime":"2026-09-24 08:30","pubTimestamp":1790209807,"startTime":"0","endTime":"0","summary":"An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast has secured U.S. FDA approval for a new T-cell Proliferation Inhib...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-wins-fda-nod-for-new-potency-assay-on-ryoncil-batches?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-wins-fda-nod-for-new-potency-assay-on-ryoncil-batches?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","LABU","NVIB","IDNA","BK4139","LFSC","MEDI","MRNY","GNMX","RSPH","IEIH","MESO","FRTY","MRNX","GDOC","TBXU","XLVX","BBP","BK4588","PSCH","PINK","SYNB","IYH","BK4585","BMED","TECB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669147769","title":"Lucid Diagnostics advances Medicare reimbursement and coding infrastructure","url":"https://stock-news.laohu8.com/highlight/detail?id=2669147769","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669147769?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:29","pubTimestamp":1790083753,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics ( ($LUCD) ) has provided an update. On September 22, 2026, Lucid Diagnostics announced key advances in payment, billing and codin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-advances-medicare-reimbursement-and-coding-infrastructure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-advances-medicare-reimbursement-and-coding-infrastructure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0433182093.SGD","IE00B775SV38.USD","BK4082","LNGR","LU0868494617.USD","REZ","LU1150488135.SGD","BK4099","XLVI","MHIP","DVXV","BMED","IEHS","LU1084165304.USD","PINK","TRUH","LU0310799852.SGD","LCID","XLVX","HTEC","MHIG","IE00B3S45H60.SGD","FHLC","IYH","BK4585","LUCD","BK4551","CURE","LU0708994859.HKD","PSCH","SG9999014013.SGD","AGNG","LCDL","JHMH","FXH","LU0203347892.USD","PTH","XHE","RSPH","LU0310800379.SGD","TMED","RXD","LCIZ","LU1267930490.SGD","BK4588","MEDI","IHI","SG9999014039.USD","IHF","HCA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669442151","title":"Ultragenyx price target raised to $35 from $32 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2669442151","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669442151?lang=en_us&edition=fundamental","pubTime":"2026-09-21 17:10","pubTimestamp":1789981807,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Ultragenyx (RARE) to $35 from $32 and keeps an Overweight rating on the shares following FDA approval of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ultragenyx-price-target-raised-to-35-from-32-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ultragenyx-price-target-raised-to-35-from-32-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","MRNX","GDOC","IYH","FRTY","IEIH","LFSC","BK4139","TECB","MEDI","NVIB","TBXU","LABU","SYNB","RSPH","IDNA","GNMX","PINK","PSCH","MRNY","BMED","RARE","BK4588","BBP","XLVX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668973580","title":"Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide","url":"https://stock-news.laohu8.com/highlight/detail?id=2668973580","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668973580?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:05","pubTimestamp":1789761914,"startTime":"0","endTime":"0","summary":"Amneal Pharmaceuticals (AMRX) “announced that the U.S. Food and Drug Administration has approved its lanreotide injection, 120 mg/0.5 mL, in a ster...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amneal-pharmaceuticals-announces-fda-approval-and-launch-of-lanreotide-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amneal-pharmaceuticals-announces-fda-approval-and-launch-of-lanreotide-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TBXU","IDNA","NVIB","SYNB","XLVX","BBP","BK4007","PSCH","RSPH","GDOC","PINK","FRTY","GNMX","BK4588","MRNY","IEIH","TECB","BMED","IYH","LABU","MEDI","AMRX","IBB","BK4585","MRNX","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668282679","title":"Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111","url":"https://stock-news.laohu8.com/highlight/detail?id=2668282679","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668282679?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:35","pubTimestamp":1789731320,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics (ABEO) “congratulated” Ultragenyx Pharmaceutical (RARE) on the U.S. Food and Drug Administration, FDA, approval of FAYUVI, also...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abeona-therapeutics-congratulated-ultragenyx-on-u-s-fda-approval-of-ux111-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abeona-therapeutics-congratulated-ultragenyx-on-u-s-fda-approval-of-ux111-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","IDNA","MRNY","LFSC","IEIH","PSCH","BK4139","SYNB","MEDI","IYH","GNMX","MRNX","RSPH","PINK","BMED","ABEO","BK4585","RARE","TECB","BBP","BK4588","FRTY","LABU","IBB","NVIB","TBXU","XLVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668994030","title":"Ultragenyx confirms FDA approval of Fayuvi","url":"https://stock-news.laohu8.com/highlight/detail?id=2668994030","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668994030?lang=en_us&edition=fundamental","pubTime":"2026-09-18 03:55","pubTimestamp":1789674924,"startTime":"0","endTime":"0","summary":"Ultragenyx (RARE) announced that the U.S. FDA granted standard full approval of Fayuvi, also known as UX111, for the treatment of pediatric patient...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ultragenyx-confirms-fda-approval-of-fayuvi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ultragenyx-confirms-fda-approval-of-fayuvi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IEIH","LFSC","BBP","SYNB","TECB","RARE","PINK","BMED","IBB","BK4585","XLVX","PSCH","BK4588","IDNA","MEDI","BK4139","GDOC","IYH","NVIB","GNMX","FRTY","MRNX","LABU","TBXU","MRNY","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668996120","title":"Nuvation Bio announces FDA approval of sNDA for Ibtrozi","url":"https://stock-news.laohu8.com/highlight/detail?id=2668996120","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668996120?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:35","pubTimestamp":1789644932,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) announced that the U.S. FDA has approved a supplemental New Drug Application for Ibtrozi, a ROS1 inhibitor approved for the tre...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvation-bio-announces-fda-approval-of-snda-for-ibtrozi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvation-bio-announces-fda-approval-of-snda-for-ibtrozi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRTY","IDNA","TBXU","BMED","BK4588","LABU","PSCH","RSPH","GDOC","MRNX","BK4007","PINK","SYNB","IBB","MEDI","GNMX","NUVB","LFSC","TECB","XLVX","MRNY","BK4585","IYH","IEIH","NVIB","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668963474","title":"Bayer receives FDA approval for Kerendia for CKD with type 1 diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2668963474","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668963474?lang=en_us&edition=fundamental","pubTime":"2026-09-17 17:30","pubTimestamp":1789637420,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced that theFDA approved Kerendia to reduce urinary albumin-to-creatinine ratio, which is expected to reduce the risk of sustai...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-receives-fda-approval-for-kerendia-for-ckd-with-type-1-diabetes-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-receives-fda-approval-for-kerendia-for-ckd-with-type-1-diabetes-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TECB","BBP","SYNB","NVIB","BAYRY","BK4588","BK4007","MRNX","IYH","IBB","BK4585","TBXU","GDOC","LABU","XLVX","IDNA","RSPH","MRNY","MEDI","IEIH","PINK","LFSC","BMED","GNMX","FRTY","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667671746","title":"ASX biotech expands diagnostics portfolio after FDA approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2667671746","media":"Morning Star AU","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667671746?lang=en_us&edition=fundamental","pubTime":"2026-09-16 00:00","pubTimestamp":1789488000,"startTime":"0","endTime":"0","summary":"Telix Pharmaceutical’s (ASX.TLX) Pixclara becomes the first positron emission tomography, or PET, imaging agent for glioma brain cancer to receive approval from the US Food and Drug Administration.Why","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"morningstar_stock","url":"https://www.morningstar.com.au/stocks/asx-biotech-expands-diagnostics-portfolio-after-fda-approval","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.morningstar.com.au/stocks/asx-biotech-expands-diagnostics-portfolio-after-fda-approval","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_stock","symbols":["XLVX","PINK","PSCH","MRNX","MRNY","IBB","TECB","RSPH","BK4588","GDOC","SYNB","IEIH","BMED","GNMX","XBIX","MEDI","BK4585","IDNA","BBP","IYH","TBXU","FRTY","LABU","NVIB","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667643557","title":"Barclays downgrades Scholar Rock on valuation after FDA approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2667643557","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667643557?lang=en_us&edition=fundamental","pubTime":"2026-09-15 17:10","pubTimestamp":1789463419,"startTime":"0","endTime":"0","summary":"Barclays analyst Etzer Darout downgraded Scholar Rock (SRRK) to Equal Weight from Overweight with a price target of $58, up from $55. The approval ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/barclays-downgrades-scholar-rock-on-valuation-after-fda-approval-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/barclays-downgrades-scholar-rock-on-valuation-after-fda-approval-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","GDOC","IYH","FRTY","CDIG","IEIH","LFSC","TECB","MEDI","NVIB","TSPA","TBXU","LABU","SYNB","RSPH","IDNA","TACU","GNMX","PINK","PSCH","MRNY","BMED","BBP","XLVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667661630","title":"Biofrontera announces FDA approval of Ameluz supplemental new drug application","url":"https://stock-news.laohu8.com/highlight/detail?id=2667661630","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667661630?lang=en_us&edition=fundamental","pubTime":"2026-09-14 21:35","pubTimestamp":1789392922,"startTime":"0","endTime":"0","summary":"Biofrontera (BFRI) announced that the FDA has approved the company’s supplemental new drug application, or sNDA, for Ameluz topical gel, 10%, in co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biofrontera-announces-fda-approval-of-ameluz-supplemental-new-drug-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biofrontera-announces-fda-approval-of-ameluz-supplemental-new-drug-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","MRNX","TECB","MEDI","GDOC","GNMX","LABU","LFSC","IYH","MRNY","BK4007","BK4588","NVIB","FRTY","IDNA","BFRI","XLVX","BBP","PSCH","IEIH","SYNB","RSPH","PINK","IBB","BK4585","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667066661","title":"Scholar Rock Wins FDA Approval for SMA Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2667066661","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667066661?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:32","pubTimestamp":1789389127,"startTime":"0","endTime":"0","summary":"The latest update is out from Scholar Rock Holding ( ($SRRK) ). On September 11, 2026, Scholar Rock announced U.S. FDA approval of ISEMBYLD (apiteg...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/scholar-rock-wins-fda-approval-for-sma-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/scholar-rock-wins-fda-approval-for-sma-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IYH","IEIH","BBP","MRNY","MEDI","TECB","BK4588","MRNX","SYNB","LABU","FRTY","PINK","LFSC","XLVX","IBB","BK4585","TBXU","PSCH","IDNA","GDOC","RSPH","NVIB","BMED","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667134663","title":"Scholar Rock price target raised to $84 from $76 at BMO Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2667134663","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667134663?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:36","pubTimestamp":1789385772,"startTime":"0","endTime":"0","summary":"BMO Capital raised the firm’s price target on Scholar Rock (SRRK) to $84 from $76 and keeps an Outperform rating on the shares. The FDA approval of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-price-target-raised-to-84-from-76-at-bmo-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-price-target-raised-to-84-from-76-at-bmo-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRTY","IBRN","MRNX","BK4585","IDNA","MRNY","SRRK","THNR","IBB","SYNB","GDOC","BBP","IYH","GNMX","NVIB","TECB","MEDI","LABU","XLVX","BK4588","TBXU","IEIH","BMED","PINK","PSCH","BK4139","LFSC","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667635862","title":"Telix Wins FDA Nod for First FET-PET Glioma Imaging Drug Pixclara","url":"https://stock-news.laohu8.com/highlight/detail?id=2667635862","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667635862?lang=en_us&edition=fundamental","pubTime":"2026-09-14 06:54","pubTimestamp":1789340092,"startTime":"0","endTime":"0","summary":"The latest update is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix Pharmaceuticals has secured U.S. FDA approval for Pixclara, the first FET-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-wins-fda-nod-for-first-fet-pet-glioma-imaging-drug-pixclara?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-wins-fda-nod-for-first-fet-pet-glioma-imaging-drug-pixclara?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","BK4139","LABU","BK4588","NVIB","LFSC","MRNX","BK4179","BK4585","TLX","XLVX","MEDI","GNMX","BBP","IBB","GDOC","FRTY","IYH","TBXU","IEIH","IDNA","RSPH","PSCH","PINK","SYNB","TECB","FET","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666577803","title":"Scholar Rock announces FDA approval of isembyld","url":"https://stock-news.laohu8.com/highlight/detail?id=2666577803","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666577803?lang=en_us&edition=fundamental","pubTime":"2026-09-12 06:30","pubTimestamp":1789165818,"startTime":"0","endTime":"0","summary":"Scholar Rock (SRRK) announced that the FDA has approved isembyld for the treatment of spinal muscular atrophy in adults and children two years of a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-announces-fda-approval-of-isembyld-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-announces-fda-approval-of-isembyld-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNMX","BK4588","TECB","LABU","MRNX","THNR","XLVX","TBXU","PSCH","PINK","GDOC","BK4139","IEIH","BK4585","IYH","BMED","RSPH","SRRK","LFSC","BBP","MEDI","IBB","NVIB","SYNB","MRNY","IBRN","FRTY","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666795715","title":"Pharming wins FDA nod to extend Joenja use to younger APDS children","url":"https://stock-news.laohu8.com/highlight/detail?id=2666795715","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666795715?lang=en_us&edition=fundamental","pubTime":"2026-09-12 02:32","pubTimestamp":1789151567,"startTime":"0","endTime":"0","summary":"Pharming Group ( ($NL:PHARM) ) has provided an announcement. Pharming has secured U.S. FDA approval for new 40 mg and 50 mg twice-daily doses of Jo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pharming-wins-fda-nod-to-extend-joenja-use-to-younger-apds-children?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pharming-wins-fda-nod-to-extend-joenja-use-to-younger-apds-children?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TECB","RSPH","TBXU","PSCH","IEIH","IDNA","BBP","SYNB","BMED","GDOC","NVIB","LABU","MRNX","IYH","IBB","BK4585","LFSC","XLVX","BK4588","MEDI","FRTY","PINK","GNMX","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665458363","title":"Medicare Advantage Patients Who Get Diagnosed with Alzheimer's or Other Serious Diseases are Ditching Their Plans - and it Can Cost Them","url":"https://stock-news.laohu8.com/highlight/detail?id=2665458363","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665458363?lang=en_us&edition=fundamental","pubTime":"2026-09-05 22:15","pubTimestamp":1788617700,"startTime":"0","endTime":"0","summary":"The annual Medicare open-enrollment period runs from Oct. 15 to Dec. 7Medicare Advantage plans cover more than half of the total Medicare market of 70.5 million subscribers, according to the Centers f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","LU0211331839.USD","XLVX","BK4585","IEHS","LU1093756168.USD","LU0256863811.USD","UNHU","LU0238689110.USD","BK4588","LU1983260115.SGD","XHS","LU0070302665.USD","LU0170899867.USD","LU0417517546.SGD","LU0390134368.USD","UN","LU0320765489.SGD","BK4154","LNGR","SG9999014005.SGD","IHF","UNHG","BK4533","LU0348723411.USD","BK4566","LU0266013472.USD","IYH","SG9999014013.SGD","SG9999014021.USD","HUM","UNHW","LU0208291251.USD","FXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665354019","title":"Guardant announces FDA approval of Guardant360 CDx as companion diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2665354019","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665354019?lang=en_us&edition=fundamental","pubTime":"2026-09-05 06:15","pubTimestamp":1788560112,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced that the U.S. Food and Drug Administration has approved Guardant360 CDx as a companion diagnostic to identify patien...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-announces-fda-approval-of-guardant360-cdx-as-companion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-announces-fda-approval-of-guardant360-cdx-as-companion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLVX","HELX","GDOC","LU0889565916.HKD","PSCH","SYNB","LU0320765992.SGD","PTH","FFOX","PINK","GNOM","EKG","BK4535","MRNY","NVIB","BMED","LABU","LFSC","IEIH","TBXU","IBB","GH","IYH","BK4196","IDNA","BK4588","GNMX","MRNX","BK4585","RSPH","FRTY","MEDI","LU0109394709.USD","TECB","BK4551","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664805403","title":"Medicare Advantage Patients Who Get Diagnosed with Alzheimer's or Other Serious Diseases are Ditching Their Plans - and it Can Cost Them","url":"https://stock-news.laohu8.com/highlight/detail?id=2664805403","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664805403?lang=en_us&edition=fundamental","pubTime":"2026-09-04 01:23","pubTimestamp":1788456180,"startTime":"0","endTime":"0","summary":"The annual Medicare open-enrollment period runs from Oct. 15 to Dec. 7Medicare Advantage plans cover more than half of the total Medicare market of 70.5 million subscribers, according to the Centers f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IHF","LU0238689110.USD","LU0348723411.USD","SG9999014013.SGD","BK4585","IYH","UNHG","BK4588","UNHU","LU1093756168.USD","BK4533","LU0170899867.USD","XLVX","LU0320765489.SGD","LU0211331839.USD","LU1983260115.SGD","LU0070302665.USD","HUM","IEHS","LNGR","UN","SG9999014005.SGD","LU0256863811.USD","LU0417517546.SGD","UNHW","XHS","FXH","LU1093756325.SGD","LU0208291251.USD","SG9999014021.USD","LU0266013472.USD","LU0390134368.USD","BK4154"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664443848","title":"Medicare Advantage Patients Who Get Diagnosed with Alzheimer's or Other Serious Diseases are Ditching Their Plans - and it Can Cost Them","url":"https://stock-news.laohu8.com/highlight/detail?id=2664443848","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664443848?lang=en_us&edition=fundamental","pubTime":"2026-09-03 00:04","pubTimestamp":1788365040,"startTime":"0","endTime":"0","summary":"The annual Medicare open-enrollment period runs from Oct. 15 to Dec. 7Medicare Advantage plans cover more than half of the total Medicare market of 70.5 million subscribers, according to the Centers f","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IEHS","HUM","BK4585","SG9999014013.SGD","SG9999014021.USD","UNHW","IYH","BK4588","LU0256863811.USD","LU0390134368.USD","LU0208291251.USD","BK4533","BK4154","XHS","LU1093756325.SGD","LU0266013472.USD","LU0417517546.SGD","LNGR","LU0238689110.USD","UNHG","SG9999014005.SGD","LU0070302665.USD","IHF","FXH","LU0170899867.USD","LU0320765489.SGD","BK4566","LU1983260115.SGD","LU0211331839.USD","UN","XLVX","LU0348723411.USD","UNHU","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":81,"code":"91000000","status":"200"}]}}